Tokenized securities are moving from what was once theory to regulated market infrastructure. For the first time, pursuant to an SEC exemptive order, third parties may be able to tokenize and facilitate trading of your company’s stock unless you affirmatively
Latest from Goodwin Procter - Page 2
Sanofi and Regeneron Expand Immunology Collaboration in Deal Worth Up to $8 Billion
On October 1, 2026, Sanofi and Regeneron Pharmaceuticals, Inc. (“Regeneron”) announced an expansion of their existing immunology collaboration to develop and commercialize four long-acting antibodies. Sanofi will pay Regeneron $1 billion upfront, with up to an additional $7 billion in
Celltrion Launches Omalizumab Biosimilar in the United States
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first and only FDA-approved interchangeable biosimilar to Genentech and Novartis’s XOLAIR® (omalizumab).
As we previously reported, the FDA approved the
Sandoz and mABxience Announce Collaboration for Proposed Emicizumab Biosimilar
On September 18, 2026, Sandoz announced a licensing, development, manufacturing, and commercialization agreement with mAbxience for a proposed biosimilar to Genentech’s HEMLIBRA® (emicizumab). HEMLIBRA® is approved for the treatment of hemophilia A.
According to Sandoz, the collaboration would add its
Dave Lynn Discusses SEC Priorities at CCR Corp’s 2026 Proxy Disclosure Conference
At the 2026 Proxy Disclosure Conference & 23rd Annual Executive Compensation Conference in Orlando, Dave Lynn led a panel on the latest developments from the Division of Corporation Finance. Dave Lynn is a Senior Editor of TheCorporateCounsel.net, CompensationStandards.com and The
SEC Posts Notice of Nasdaq Amendment to Minimum Stock Price Rule for Initial Listings
On October 7, the SEC posted notice and immediate effectiveness of a Nasdaq amendment to Listing Rule 5505, which will require a minimum $4 stock price for initial listing on the Nasdaq Capital Market. This will eliminate the alternative price
ISS STOXX Governance Announces Results of Annual Global Benchmark Policy Survey
On October 7, ISS STOXX Governance (ISS) announced the results of its annual global benchmark policy survey. This survey is conducted as part of the annual policy development process that ISS undertakes to determine whether it should make changes
Division of Corporation Finance Issues Another Retail Voting Program No-Action Letter
On September 29, 2026, the SEC’s Division of Corporation Finance issued a no-action letter in response to a request from Tesla, Inc. (Tesla) indicating that the Division would not recommend enforcement action to the Commission if Tesla proceeded with its
Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach
On September 22, 2026, Biocon Biologics Limited (“Biocon”) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending marketing authorization for PEBRILZO® (pertuzumab), its biosimilar to Genentech’s PERJETA®.
According to
Janssen Granted Preliminary Injunction Against Golimumab Biosimilar
On September 30, 2026, the U.S. District Court for the District of Delaware issued an order granting Janssen Biotech, Inc. and Janssen Sciences Ireland UC’s (collectively, “Janssen”) motion for a preliminary injunction in Janssen Biotech, Inc. v. Accord BioPharma, Inc.,